Univeristy of Thessaly
Larissa, Thessaly, 41110, Greece
Completed
NCT Number: NCT04254211
Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in EVAR
This study investigated the association of chronic inflammatory markers with the clinical outcome after endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm.
Completed
Looking for future studies?
Notify MeKey information
About this study
The study included 230 consecutive AAA patients, treated electively by EVAR from March 2016 to February 2019. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively.Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- AAA
- Elective
- EVAR
Exclusion criteria
- Emergency
- Open surgery
Treatment and study plan
NLR
Otherneutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
Other names: PLR
Primary outcomes
-
NLR major cardiovascular events (MACE)
Time frame: Day 4 postopertively
NLR indicator for major cardiovascular events (MACE)
-
PLR major cardiovascular events (MACE)
Time frame: Day 4 postopertively
PLR indicator for major cardiovascular events (MACE)
-
NLR acute kidney injury (AKI)
Time frame: Day 4 postopertively
NLR indicator for acute kidney injury (AKI)
-
PLR acute kidney injury (AKI)
Time frame: Day 4 postopertively
PLR indicator for acute kidney injury (AKI)
-
NLR death
Time frame: Day 4 postopertively
NLR indicator for death
-
PLR death
Time frame: Day 4 postopertively
PLR indicator for death
Sponsors and collaborators
Lead sponsor
University of Thessaly
Other
Registry information
Official study title
Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio as Predictors for Adverse Events in Endovascular Aneurysm Repair for Abdominal Aorticaneurysm
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2019
- First posted
- Feb 5, 2020
- Registry last updated
- Apr 28, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.